In-situ genomic DNA chip for detection of cancer
OwnerFeng Jianginventor
Life of this patent
Estimating the term…
Abstract
An in situ genomic DNA chip can be used directly on clinical specimens in situ for detecting, diagnosing and/or predicting diseases, especially diseases characterized by a genetic aberration such as cancers, by simultaneous detection of one or more unique genetic aberrations using one or more multiple specific probes. The present invention offers high sensitivity for detection of such genetic aberrations and, further, has substantial implications for large-scale population-based molecular epidemiologic studies and therapeutic interventions.
Claims19
An in situ genomic DNA array for detection of a disease with genetic aberrations, said DNA array comprising;
- a substrate;
- and
- a plurality of genomic DNA probes immobilized to said substrate;
- wherein said plurality of genomic DNA probes are selected to identify a genetic signature of said disease and are capable of interphase multiple fluorescence in situ hybridization with a tissue or cell sample.
A method for detecting a disease with genetic aberrations, said method comprising:
- incubating a tissue or cell sample with an in situ genomic DNA array comprising a plurality of genomic DNA probes selected to identify a genetic signature of said disease and capable of interphase multiple fluorescence in situ hybridization with said tissue or cell sample;
- detecting a signal from said in situ genomic DNA array;
- and
- producing a diagnosis based on the signal detected from said in situ genomic DNA array.
A kit comprising:
- at least one genetic probe, wherein the genetic probe comprises a nucleotide sequence specific to a gene having a genetic aberration in a diseased state,
- a chromosomal centromeric probe consisting essentially of a nucleotide sequence of the chromosome centromere corresponding to the gene,
- wherein said genetic probe and said chromosomal centromeric probe each further comprise a fluorescent label, and
- a suitable container.
A kit comprising:
- at least four genetic probes, wherein each of the genetic probes comprise a nucleotide sequence specific to a first, second, third, and fourth gene, each having a genetic aberration in a diseased state,
- a chromosomal centromeric probe, each consisting essentially of a nucleotide sequence of the chromosome centromere corresponding separately to the first, second, third, and fourth gene,
- wherein said genetic probes and said chromosomal centromeric probes each further comprise a fluorescent label, and
- a suitable container.
Dependencies are inferred from the claim text.